FDA
-
-
-
-
-
-
-
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
-
-
-
-
-
-
-
Revolution Medicines receives FDA early access authorization for pancreatic cancer pill
-
-
-
-
-
-
-
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
-
-
-
-
-
-
-
Revolution (RVMD) PT Raised to $76 at Raymond James
-
-
-
-
-
-
-
Revolution Medicines (RVMD) Enters Into $2B Flexible Funding Agreement with Royalty Pharma
-
-
-
-
-
-
-
Biotech outlook for 2025: Stifel
-
-
-
-
-
-
-
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
326,426 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

